Philipp J. Jost

15.2k total citations · 1 hit paper
108 papers, 4.5k citations indexed

About

Philipp J. Jost is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Philipp J. Jost has authored 108 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 31 papers in Oncology and 28 papers in Cancer Research. Recurrent topics in Philipp J. Jost's work include Cancer Genomics and Diagnostics (18 papers), Cell death mechanisms and regulation (18 papers) and Acute Myeloid Leukemia Research (10 papers). Philipp J. Jost is often cited by papers focused on Cancer Genomics and Diagnostics (18 papers), Cell death mechanisms and regulation (18 papers) and Acute Myeloid Leukemia Research (10 papers). Philipp J. Jost collaborates with scholars based in Germany, Austria and United States. Philipp J. Jost's co-authors include Andreas Strasser, Shigekazu Nagata, Jürgen Ruland, Thomas Kaufmann, John Silke, Monica Yabal, Philippe Bouillet, Mads Gyrd‐Hansen, Christian Peschel and Rune Busk Damgaard and has published in prestigious journals such as Nature, Science and Journal of Clinical Oncology.

In The Last Decade

Philipp J. Jost

101 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Many Roles of FAS Receptor Signaling in the Immune System

2009 723 citations Andreas Strasser, Philipp J. Jost et al. profile →

Peers

Countries citing papers authored by Philipp J. Jost

Since Specialization

Citations

This map shows the geographic impact of Philipp J. Jost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp J. Jost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp J. Jost more than expected).

Fields of papers citing papers by Philipp J. Jost

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philipp J. Jost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp J. Jost. The network helps show where Philipp J. Jost may publish in the future.

Co-authorship network of co-authors of Philipp J. Jost

This figure shows the co-authorship network connecting the top 25 collaborators of Philipp J. Jost. A scholar is included among the top collaborators of Philipp J. Jost based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philipp J. Jost. Philipp J. Jost is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	155P Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1 2024 ·Immuno-Oncology Technology ·Anne C. Chiang, (unknown), (unknown), (unknown), Noemı́ Reguart, (unknown), Philipp J. Jost, (unknown), Rafał Stec, (unknown), (unknown), Weiguo Jiang, Ali Hamidi, Amanda Parkes, (unknown)	1
2	530P Real-world effectiveness and predictive biomarker analysis of TAS-102+bevacizumab vs. regorafenib vs. TAS-102 in metastatic colorectal cancer: A multicenter cohort study 2024 ·Annals of Oncology ·Andreas Seeber, (unknown), Bernhard Doleschal, Hossein Taghizadeh, (unknown), Florian Moik, (unknown), Ludwig Wagner, (unknown), (unknown), (unknown), Arno Amann, Dominik Wolf‎, Richard Greil, Philipp J. Jost, Thomas Winder, Holger Rumpold, (unknown), Armin Gerger, Jakob M. Riedl	0
3	Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update 2024 ·Journal of Clinical Oncology ·Afshin Dowlati, Horst-Dieter Hummel, Stéphane Champiat, M.E. Olmedo, Michael Boyer, Kai He, Neeltje Steeghs, Hiroki Izumi, Melissa L. Johnson, Tatsuya Yoshida, Hasna Bouchaab, Hossein Borghaei, Enriqueta Felip, Philipp J. Jost, Shirish M. Gadgeel, (unknown), (unknown), Pablo Martínez, Amanda Parkes, Luis Paz‐Ares	22
4	Incidence of Diabetes Mellitus and Its Impact on Outcomes in Patients Undergoing Surgical Pancreatectomy for Non-Malignant and Malignant Pancreatobiliary Diseases—A Retrospective Analysis 2023 ·Journal of Clinical Medicine ·Anna Schranz, (unknown), Faisal Aziz, Doris Wagner, Peter Kornprat, Robert Sucher, Philipp J. Jost, Albert Wölfler, Thomas R. Pieber, Harald Sourij, Jakob M. Riedl, Felix Aberer	1
5	Epigallocatechin gallate inhibits Francisella tularensis growth and suppresses the function of DNA-binding protein HU 2023 ·Microbial Pathogenesis ·(unknown), Philipp J. Jost, Pavel Řehulka, (unknown), Marek Link, (unknown)	3
6	KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial 2023 ·Clinical Cancer Research ·Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, Annette Reichardt, Kirsten Sundby Hall, (unknown), Silke Cameron, Peter Hohenberger, Harri Sihto, Philipp J. Jost, Lars H. Lindner, Sebastian Bauer, Bengt Nilsson, Raija Kallio, (unknown), Peter Reichardt	13
7	The coming decade in precision oncology: six riddles 2022 ·Nature reviews. Cancer ·Adam Wahida, Lars Buschhorn, Stefan Fröhling, Philipp J. Jost, Andreas Schneeweiß, Peter Lichter, Razelle Kurzrock	121
8	The BCL-2 family member BOK promotes KRAS-driven lung cancer progression in a p53-dependent manner 2022 ·Oncogene ·(unknown), Enkhtsetseg Munkhbaatar, Ulrike Höckendorf, Michelle Dietzen, (unknown), Martina Anton, Anne Jacob, Katja Steiger, Wilko Weichert, Luka Brčić, Nicholas McGranahan, Caterina Branca, Thomas Kaufmann, Michael A. Dengler, Philipp J. Jost	10
9	Trends and Patterns in the Public Awareness of Palliative Care, Euthanasia, and End-of-Life Decisions in 3 Central European Countries Using Big Data Analysis From Google: Retrospective Analysis 2021 ·Journal of Medical Internet Research ·(unknown), (unknown), G Hofmann, Elisabeth Andritsch, (unknown), (unknown), Eva Katharina Masel, Philipp J. Jost, Martin Pichler	8
10	PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer 2021 ·JCI Insight ·(unknown), Sebastian Lange, H. Carlo Maurer, Kenneth P. Olive, Rickmer Braren, Nicole Pfarr, (unknown), Alexander Muckenhuber, Moritz Jesinghaus, Katja Steiger, Wilko Weichert, Helmut Friess, Roland M. Schmid, Hana Algül, Philipp J. Jost, Juliane Ramser, Christine Fischer, Anne S. Quante, Maximilian Reichert, Michael Quante	7
11	Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity 2021 ·Cancers ·Christoph Suppan, Florian Posch, (unknown), (unknown), Daniel Steiner, (unknown), (unknown), (unknown), Robert E. Hammer, (unknown), Philipp J. Jost, Nadia Dandachi, Sigurd Lax, Marija Balić	10
12	1184P Necroptosis establishes an inflammatory tumor immune microenvironment acting as tumor suppressor in lung adenocarcinoma 2021 ·Annals of Oncology ·(unknown), (unknown), Michelle Dietzen, Sebastian Vosberg, Enkhtsetseg Munkhbaatar, Nicholas McGranahan, Philipp J. Jost	0
13	TNFR2 induced priming of the inflammasome leads to a RIPK1-dependent cell death in the absence of XIAP 2019 ·Cell Death and Disease ·(unknown), Lisanne M. Spilgies, (unknown), (unknown), (unknown), Monica Yabal, Erika Owsley, Philipp J. Jost, Rebecca Marsh, Harald Wajant, Mark D. Robinson, Thomas Kaufmann, W. Wei‐Lynn Wong	28
14	Gene therapy for X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency 2017 ·Human Gene Therapy ·(unknown), (unknown), (unknown), Philipp J. Jost, Bobby Gaspar, Claire Booth	1
15	Survival control of malignant lymphocytes by anti-apoptotic MCL-1 2016 ·Leukemia ·Yuniel Fernández‐Marrero, (unknown), Thomas Kaufmann, Philipp J. Jost	31
16	Loss of XIAP facilitates switch to TNFα-induced necroptosis in mouse neutrophils 2016 ·Cell Death and Disease ·(unknown), (unknown), W. Wei‐Lynn Wong, Philipp J. Jost, Daniel Bachmann, Thomas Kaufmann	70
17	Comparison of the Radiosensitizing Effect of ATR, ATM and DNA-PK Kinase Inhibitors on Cervical Carcinoma Cells 2016 ·Folia Biologica ·Jiřina Vávrová, (unknown), Philipp J. Jost, Aleš Tichý, Martina Řezáčová, Zuzana Šinkorová, Jaroslav Pejchal	8
18	Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA 2013 ·Clinical Cancer Research ·Jacqueline Maier, Thoralf Lange, Irina Kerle, Katja Specht, Melanie Bruegel, Claudia Wickenhauser, Philipp J. Jost, Dietger Niederwieser, Christian Peschel, Justus Duyster, Nikolas von Bubnoff	60
19	Mcl-1 Is Essential for Germinal Center Formation and B Cell Memory 2010 ·Science ·Ingela B. Vikstrom, Sebastian Carotta, Katja Lüthje, Victor Peperzak, Philipp J. Jost, Stefan Glaser, Meinrad Busslinger, Philippe Bouillet, Andreas Strasser, Stephen L. Nutt, David M. Tarlinton	176
20	Bcl10/Malt1 Signaling Is Essential for TCR-Induced NF-κB Activation in Thymocytes but Dispensable for Positive or Negative Selection 2007 ·The Journal of Immunology ·Philipp J. Jost, Stéphanie Weiss, Uta Ferch, Olaf Groß, Tak W. Mak, Christian Peschel, Jürgen Ruland	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact